Header Logo

Connection

Yaping Chu to Humans

Back to Details
This is a "connection" page, showing publications Yaping Chu has written about Humans.
Yaping Chu
Connection Strength
0.551
Humans
  1. Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10?Years CERE120 Delivery. Mov Disord. 2023 09; 38(9):1728-1736.
    View in: PubMed
    Score: 0.051
  2. Mixed pathology as a rule, not exception: Time to reconsider disease nosology. Handb Clin Neurol. 2023; 192:57-71.
    View in: PubMed
    Score: 0.049
  3. GDNF signaling in subjects with minimal motor deficits and Parkinson's disease. Neurobiol Dis. 2021 06; 153:105298.
    View in: PubMed
    Score: 0.043
  4. Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain. 2020 03 01; 143(3):960-975.
    View in: PubMed
    Score: 0.040
  5. Do subjects with minimal motor features have prodromal Parkinson disease? Ann Neurol. 2018 03; 83(3):562-574.
    View in: PubMed
    Score: 0.035
  6. Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease. J Parkinsons Dis. 2016; 6(1):77-97.
    View in: PubMed
    Score: 0.030
  7. The prion hypothesis of Parkinson's disease. Curr Neurol Neurosci Rep. 2015 May; 15(5):28.
    View in: PubMed
    Score: 0.029
  8. Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. Neurobiol Dis. 2014 Sep; 69:1-14.
    View in: PubMed
    Score: 0.027
  9. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain. 2012 Jul; 135(Pt 7):2058-73.
    View in: PubMed
    Score: 0.023
  10. a-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol Dis. 2011 Jan; 41(1):71-82.
    View in: PubMed
    Score: 0.021
  11. Lewy body pathology in fetal grafts. Ann N Y Acad Sci. 2010 Jan; 1184:55-67.
    View in: PubMed
    Score: 0.020
  12. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009 Sep; 35(3):385-98.
    View in: PubMed
    Score: 0.019
  13. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis. 2007 Jan; 25(1):134-49.
    View in: PubMed
    Score: 0.016
  14. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
    View in: PubMed
    Score: 0.015
  15. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol. 2002 Aug 26; 450(3):203-14.
    View in: PubMed
    Score: 0.012
  16. In situ proximity labeling identifies Lewy pathology molecular interactions in the human brain. Proc Natl Acad Sci U S A. 2022 02 01; 119(5).
    View in: PubMed
    Score: 0.011
  17. Temporal evolution of microglia and a-synuclein accumulation following foetal grafting in Parkinson's disease. Brain. 2019 06 01; 142(6):1690-1700.
    View in: PubMed
    Score: 0.009
  18. Widespread Striatal Delivery of GDNF from Encapsulated Cells Prevents the Anatomical and Functional Consequences of Excitotoxicity. Neural Plast. 2019; 2019:6286197.
    View in: PubMed
    Score: 0.009
  19. Detecting Alpha Synuclein Seeding Activity in Formaldehyde-Fixed MSA Patient Tissue by PMCA. Mol Neurobiol. 2018 Nov; 55(11):8728-8737.
    View in: PubMed
    Score: 0.009
  20. Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathol Commun. 2017 06 16; 5(1):47.
    View in: PubMed
    Score: 0.008
  21. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017 Jan; 81(1):46-57.
    View in: PubMed
    Score: 0.008
  22. PGC-1a Promoter Methylation in Parkinson's Disease. PLoS One. 2015; 10(8):e0134087.
    View in: PubMed
    Score: 0.007
  23. Analysis of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and increased vulnerability of callosal axons in Huntington's disease. Hum Mol Genet. 2015 Sep 15; 24(18):5285-98.
    View in: PubMed
    Score: 0.007
  24. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014 Sep; 10(5):571-81.
    View in: PubMed
    Score: 0.007
  25. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013 Aug; 136(Pt 8):2419-31.
    View in: PubMed
    Score: 0.006
  26. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord. 2011 Jan; 26(1):27-36.
    View in: PubMed
    Score: 0.005
  27. ?-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and ?-amyloid accumulation. Eur J Neurosci. 2010 Oct; 32(7):1223-38.
    View in: PubMed
    Score: 0.005
  28. Doublecortin expression in adult cat and primate cerebral cortex relates to immature neurons that develop into GABAergic subgroups. Exp Neurol. 2009 Apr; 216(2):342-56.
    View in: PubMed
    Score: 0.005
  29. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008 Dec 15; 23(16):2303-6.
    View in: PubMed
    Score: 0.005
  30. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008 May; 14(5):504-6.
    View in: PubMed
    Score: 0.004
  31. Postmortem study of deep brain stimulation of the anterior thalamus: case report. Neurosurgery. 2008 Feb; 62(2):E530-2; discussion E532.
    View in: PubMed
    Score: 0.004
  32. Neuropathological study 16 years after autologous adrenal medullary transplantation in a Parkinson's disease patient. Mov Disord. 2007 Aug 15; 22(11):1630-3.
    View in: PubMed
    Score: 0.004
  33. Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res. 2007 May 25; 1147:77-88.
    View in: PubMed
    Score: 0.004
  34. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol. 2006 Aug; 60(2):260-4.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.